Santen Pharmaceutical has patented a preventive eye drop for glaucoma or ocular hypertension, combining isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with timolol or its salt. The formulation excludes tafluprost. GlobalData’s report on Santen Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Santen Pharmaceutical, Nanoparticle drug conjugates was a key innovation area identified from patents. Santen Pharmaceutical's grant share as of May 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11974994B2) discloses a novel preventive eye drop for the treatment of glaucoma or ocular hypertension. The eye drop formulation comprises a unique combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with timolol or a salt thereof. The concentration of isopropyl in the eye drop ranges from 0.001 to 0.1 w/v %, while the timolol concentration ranges from 0.01 to 5 w/v %, with a specific range of 0.1 to 0.5 w/v % for optimal efficacy.
Moreover, the patent claims specify that the eye drop formulation can effectively lower intraocular pressure, making it suitable for treating both glaucoma and ocular hypertension. The inclusion of timolol maleate as the preferred form of timolol in the eye drop further enhances its therapeutic potential. The precise concentrations of the active ingredients in the eye drop, as outlined in the claims, highlight the meticulous formulation process undertaken to ensure the desired pharmacological effects. This patent represents a significant advancement in the field of ophthalmic pharmaceuticals, offering a promising solution for individuals suffering from these vision-related conditions.
To know more about GlobalData’s detailed insights on Santen Pharmaceutical, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
